An experimental patient-specific whole-genome liquid biopsy detected lung cancer DNA associated with recurrence months before tumors were visible on imaging, in a study focused on stage IA lung adenocarcinoma. The findings point to a potential shift from imaging-confirmed recurrence to molecular detection-led surveillance. Because this is an experimental design, key implementation questions remain—such as false-positive control, lead-time consistency across patients, and how to align intervention thresholds with clinically meaningful benefit. Even so, the work provides a proof point that genomic recurrence signals can emerge during periods when standard imaging cannot yet resolve disease. For development teams, the study reinforces the need to pair sensitivity gains with rigorous clinical actionability frameworks so earlier detection translates into improved outcomes rather than earlier anxiety or overtreatment.